Dosing and concentration
For Barth syndrome, the specified medicinal preparation uses 40 mg under the skin once daily in patients weighing at least 30 kg; adults with severe kidney impairment require a lower dose. At its concentration of 80 mg/mL, 40 mg occupies 0.5 mL. This schedule applies to that condition and preparation, not general fatigue or ageing.
The Barth syndrome schedule is not a fatigue or anti-ageing prescription. Different amounts or short courses cannot be assumed to offer the same benefit in someone without that condition.
A preparation's total milligrams and concentration must be recorded separately. Half a millilitre of a different solution may contain a very different amount. Kidney function is particularly relevant to exposure, so a concentration calculation cannot replace individual review.
Preparation and reconstitution
The approved elamipretide solution is ready to use; it should not be reconstituted or diluted with bacteriostatic water. It is a defined formulation, not a lyophilised vial.
Lyophilised SS-31 means freeze-dried research material. Preparing it requires documentation of the exact substance, compatible diluent, concentration and storage limit. Bacteriostatic water's preservative does not establish equivalence to the medicinal solution or make contaminated material sterile.
Do not mix SS-31 with MOTS-c or other products in the same syringe without confirmed compatibility. Keep the original container and record strength, preparation or opening date and discard date.
Administration
The medicinal formulation uses the abdomen or outer thigh for injection under the skin, with site rotation. Have the correct device and measuring technique demonstrated before home use. These instructions do not apply to delivery into a vein.
Use clean hands and a clean work area, inspect the solution as directed and use new sterile equipment. Avoid tender, bruised, red, hardened or scarred skin. Put used sharps directly into a sharps container. An injection near a tired muscle does not target that muscle's mitochondria selectively.
Local reactions can be troublesome. Keep a record of location, size, timing and persistence rather than repeatedly using the least sensitive site. A spreading or severe reaction needs assessment, and uncertain delivery should not prompt an automatic repeat dose.
Oral versus subcutaneous delivery
Injection under the skin bypasses digestive breakdown and is the route used in the medicinal programme. The formulation has measured high systemic absorption into the bloodstream, but that finding belongs to that preparation and route.
An ordinary oral SS-31 product cannot be assumed to reach the same exposure. A peptide may need a specialised delivery system to survive gut processing and cross the intestinal barrier. A local gut effect is not the established reason for SS-31's mitochondrial-disease use; the intended targets include tissues beyond the digestive tract.
Higher bloodstream exposure alone does not prove better function. The clinical question remains whether the intervention improves a meaningful outcome for the person's condition.
Half-life
SS-31 exposure falls over hours rather than a full week, and kidney function affects clearance. The documented U.S. label does not provide a single elimination half-life number. The frequently repeated “four hours” should not be treated as a universal value or a reason to redose throughout the day.
Storage
The documented ready-to-use medicinal vial is refrigerated at 2–8°C before use and must not be frozen. After opening, its instructions permit refrigerated or specified room-temperature storage and require disposal after eight days. This limit belongs to that formulation.
A lyophilised or reconstituted SS-31 preparation needs its own documented stability instructions. Do not borrow the eight-day rule or a general 28-day rule. Record opening and preparation dates, protect the container as directed and avoid direct contact with freezing packs during travel.
Contraindications and side effects
Serious allergy is a contraindication for the medicinal formulation. Injection-site reactions are common. A severe or spreading rash, breathing difficulty or facial swelling needs urgent assessment, and a serious allergic reaction should not be tested again with a smaller amount.
Kidney impairment can increase exposure and requires dose review in the medicinal setting. Pregnancy, breastfeeding and uses outside the studied population need individual assessment. The ready-made formulation contains benzyl alcohol and is not for neonates.
Fatigue deserves a diagnosis. SS-31 should not replace assessment for heart disease, anaemia, sleep apnoea or endocrine disorders. New breathlessness, chest pain, fainting or profound weakness should not be interpreted as a normal mitochondrial “adjustment.”
Tracking progress and common questions
Record specific functional goals: walking a familiar route, managing stairs or completing daily tasks. Note fatigue, sleep, illness and activity level. A repeated measure under similar conditions is more useful than a vague feeling of “better mitochondria.”
“Does approval mean it is proven for anti-ageing?” No: the indication is specific. “Is every SS-31 vial the same as the medicine?” No. “Should I feel it immediately?” An immediate sensation does not establish benefit. Persistent or worsening fatigue needs a broader assessment, even if a peptide is being used.